Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

British Journal of Haematology

Volumn 105, Issue 1, 1999, Pages 127-130

  Segeren, C M ^a   Sonneveld, P ^a   Van Der Holt, B ^a   Baars, J W ^a   Biesma, D H ^a   Cornellissen, J J ^a   Croockewit, A J ^a   Dekker, A W ^a   Fibbe, W E ^a   Lowenberg B ^a   Van Marwijk Kooy, M ^a   Van Oers, M H J ^a   Rlchel, D J ^a   Schouten, H C ^a   Vellenga, E ^a   Verhoef, G E G ^a   Wijermans, P W ^a   Wittebol, S ^a   Lokhorst, H M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Induction treatment; Multiple myeloma; Rapid infusion; VAD

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUROTOXICITY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; VINCRISTINE;

EID: 0032920397     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1999.01279.x     Document Type: Article

References (14)

1. Alexanian, R., Barlogie. B. & Tucker, S. (1990) VAD-bascd regimens as primary treatment for multiple myeloma. American Journal of Hematology, 33. 86-89.
2. Alexanian. R., Yap, U.S. & Bodey. G.P. (1983) Prednisone pulse therapy for refractory multiple myeloma. Blood, 62. 572-577.
3. Anderson, H.. Scarffe, J.H.. Ranson, M.. Young. R., Wieringa, G.S., Morgenstern, G.R.. Fitzsimmons, L. & Ryder, D. (1995) VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer, 71, 326-330.
4. Altai, M.. Huguet, F., Schlaifer. D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris. J. & Laurant, G. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
5. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine. 310, 1353-1358.
6. Collin, R.. Greaves. M. & Preston, F. (1987) Potential value of vincristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma. European Journal of Haemalology. 39, 203-208.
7. Drewinko, B., Alexanian, R.. Boyer, IL, Barlogie, B. & Rubinow, S.I. (1981) The growth fraction of human myeloma cells. Blood. 57, 333-338.
8. Durie, B. & Salmon. S.E. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842-854.
9. Gottlieb, J.A.. Gutterman, J.U., McCredie, K.B., Rodriguez, V. & Frei, E. (1973) Chemotherapy of malignant lymphoma with adriamycin. Cancer Research, 33, 3024-3028.
10. Gregory, W.M.. Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334-342.
11. Jackson, D.V.. Jr. Sethi, VS., Spurr. C.L.. White, D.R., Richards, F., Stuart. J.J., Muss, H.B., Cooper, M.R. & Castle, M.C. (1981) Pharmacokinetics of vincristine infusion. Cancer Treatment Reports, 65, 1043-1048.
12. Koskela. K., Pelliniemi, T. & Remes, K. (1993) VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leukemia and Lymphoma, 10, 347-351.
13. Lokhorst, U.M., Meuwissen, O.J.A.T.. Bast, E.J.E.G. & Dekker, A.W. (1989) VAD chemotherapy for refractory multiple myeloma. British Journal of Haematology. 71, 25-30.
14. Samson, D.. Newland, A., Kearney, J., Joyner, M., Mitchell, T., Barrett, A.J., Gaminara, E., Van De Pette, J., McCarthy, D., Aston, L, Hamon, M. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882-885.